

11/23  
JB  
8/20/02

COPY OF PAPERS  
ORIGINALLY FILED

PHOE-0057

PATENT  
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AUG 14 2002

TECH CENTER 1600/290



In re application of: Clark

Serial No.: 09/504,280

Group Art Unit: 1647


Filed: February 15, 2000

Examiner: D. S. Romeo

For: MODIFIED TUMOR NECROSIS FACTOR

I, Gwilym John Owen Attwell, Registration No. 45,449 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

(On August 8, 2002)

  
Mark DeLuca, Registration No: 33,229

Assistant Commissioner  
for Patents  
Washington, D.C. 20231

Dear Sir:

**RESPONSE**

This paper is being filed in response to the Office Action dated April 8, 2002. A petition for an extension of time and the appropriate fee accompany this response. Applicants respectfully request that the following amendments be entered and that the rejection of claims in the application be reconsidered and withdrawn.

**In the Claims**

Please add new claim 24:

24. (New) The modified TNF of claim 1 wherein said PEG is covalently bound to primary amine groups on said TNF through a biocompatible linker.

08/15/2002 CCHAU1 00000060 09504280  
02 FC:215 55.00 0P  
08/15/2002 CCHAU1 00000060 09504280  
01 FC:203

Please amend claim 3 to read as follows:

3. (Amended) The modified TNF of claim 24 wherein said linker is selected from the group consisting of succinimidyl succinate, succinimidyl propionate, and N-hydroxy succinimidyl.